MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
26.43
+0.65
+2.52%
Opening 13:11 05/13 EDT
OPEN
26.06
PREV CLOSE
25.78
HIGH
26.53
LOW
25.33
VOLUME
426.98K
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
8.25
MARKET CAP
1.46B
P/E (TTM)
-8.6627
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE) and Anixa Biosciences (ANIX)
TipRanks · 6h ago
Wedbush Sticks to Their Buy Rating for Maze Therapeutics, Inc. (MAZE)
TipRanks · 9h ago
Maze Therapeutics: Buy Rating Reiterated, $57 Price Target Maintained on Strong Balance Sheet and Advancing Kidney Disease Pipeline
TipRanks · 9h ago
J.P. Morgan Remains a Buy on Maze Therapeutics, Inc. (MAZE)
TipRanks · 10h ago
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Maze Therapeutics, Inc. (MAZE)
TipRanks · 21h ago
Maze Therapeutics reports Q1 EPS (45c), consensus (63c)
TipRanks · 1d ago
Maze Therapeutics GAAP EPS of -$0.45 beats by $0.10, revenue of $20M beats by $11.5M
Seeking Alpha · 1d ago
Maze Therapeutics posts smaller than expected Q1 loss
Reuters · 1d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.